CanSino Biologics Inc (CASBF)
2.83
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
CanSino Biologics Enterprise Value: 431.77M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 431.77M |
| May 30, 2024 | 431.77M |
| May 29, 2024 | 431.77M |
| May 28, 2024 | 431.77M |
| May 24, 2024 | 251.13M |
| May 23, 2024 | 251.13M |
| May 22, 2024 | 251.13M |
| May 21, 2024 | 251.13M |
| May 20, 2024 | 251.13M |
| May 17, 2024 | 251.13M |
| May 16, 2024 | 251.13M |
| May 15, 2024 | 251.13M |
| May 14, 2024 | 251.13M |
| May 13, 2024 | 251.13M |
| May 10, 2024 | 251.13M |
| May 09, 2024 | 251.13M |
| May 08, 2024 | 251.13M |
| May 07, 2024 | 251.13M |
| May 06, 2024 | 251.13M |
| May 03, 2024 | 251.13M |
| May 02, 2024 | 251.13M |
| May 01, 2024 | 251.13M |
| April 30, 2024 | 251.13M |
| April 29, 2024 | 251.13M |
| April 26, 2024 | 251.13M |
| Date | Value |
|---|---|
| April 25, 2024 | 251.13M |
| April 24, 2024 | 251.13M |
| April 23, 2024 | 251.13M |
| April 22, 2024 | 251.13M |
| April 19, 2024 | 251.13M |
| April 18, 2024 | 251.13M |
| April 17, 2024 | 251.13M |
| April 16, 2024 | 251.13M |
| April 15, 2024 | 251.13M |
| April 12, 2024 | 251.13M |
| April 11, 2024 | 251.13M |
| April 10, 2024 | 251.13M |
| April 09, 2024 | 251.13M |
| April 08, 2024 | 251.13M |
| April 05, 2024 | 191.74M |
| April 04, 2024 | 191.74M |
| April 03, 2024 | 191.74M |
| April 02, 2024 | 191.74M |
| April 01, 2024 | 191.74M |
| March 31, 2024 | 191.74M |
| March 28, 2024 | 227.96M |
| March 27, 2024 | 227.96M |
| March 26, 2024 | 227.96M |
| March 25, 2024 | 277.45M |
| March 22, 2024 | 277.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
191.74M
Minimum
Mar 31 2024
12.67B
Maximum
Feb 17 2021
3.614B
Average
2.243B
Median
Enterprise Value Benchmarks
| Sinovac Biotech Ltd | -7.011B |
| CASI Pharmaceuticals Inc | 50.79M |
| Zai Lab Ltd | 1.153B |
| Gracell Biotechnologies Inc (DELISTED) | -- |
| Adagene Inc | 35.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.77M |
| Revenue (Quarterly) | 15.97M |
| Total Expenses (Quarterly) | 30.75M |
| EPS Diluted (Quarterly) | -0.0964 |
| Gross Profit Margin (Quarterly) | 59.55% |
| Profit Margin (Quarterly) | -148.8% |
| Earnings Yield | -30.47% |
| Normalized Earnings Yield | -34.91 |